Hepatic cytoreduction for lung and renal neuroendocrine tumor metastases
- 1 February 2024
- journal article
- research article
- Published by Elsevier in The American Journal of Surgery
- Vol. 231, 41-45
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United StatesJAMA Oncology, 2017
- Early Recurrence After Hepatectomy for Colorectal Liver Metastases: What Optimal Definition and What Predictive Factors?The Oncologist, 2016
- Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 studyThe Lancet, 2016
- Expanded criteria for carcinoid liver debulking: Maintaining survival and increasing the number of eligible patientsSurgery, 2014
- The Pathologic Classification of Neuroendocrine TumorsPancreas, 2010
- Surgical Management of Hepatic Neuroendocrine Tumor Metastasis: Results from an International Multi-Institutional AnalysisAnnals of Surgical Oncology, 2010
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Renal neuroendocrine tumorsIndian Journal of Urology, 2009
- Surgical Treatment of Neuroendocrine Metastases to the LiverJournal of the American College of Surgeons, 2003
- Clinical Score for Predicting Recurrence After Hepatic Resection for Metastatic Colorectal CancerAnnals of Surgery, 1999